COYA NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Coya Therapeutics, Inc. Common Stock · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 4.25 USD
-6.4% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is -9.2% below the Trend Line and sits at 13.4% of its 52-week range. The latest completed week returned -6.4%, after a -22.7% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 35/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: earnings are due in 13d.

Setup score 25 out of 100
Latest Close 4.25 USD 24 Jul 2026
1W Return -6.4% latest completed week
4W Return -22.7% short-term follow-through
12W Return 1.9% quarterly tape
Trend Breadth 17.3% 9 of 52 weeks active
Volume Ratio 1.1x vs 13-week average
What is working
  • The trend backdrop is active with a 2-week active streak.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -6.4% Latest completed week; four-week move -22.7%. Indicator stack 16/64 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Mixed 35/100 conviction; expected move 25.3%. News sentiment 57/100 41 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is -9.2% below the Trend Line and sits at 13.4% of its 52-week range. The latest completed week returned -6.4%, after a -22.7% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2712-week average 0.11

12-week confirmation

Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.27Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -22.7% over four weeks, 1.9% over 12 weeks, and -36.3% over one year. The current trend has remained active for 2 consecutive weeks.

Performance by holding period

1W-6.4%
4W-22.7%
12W1.9%
26W-10.0%
52W-36.3%
Active trend streak2 weeks
Active weeks in one year9
Trend breadth17.3%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.85Latest activity-pressure read.
Pressure change-12.6%Four-week change in activity pressure.
Leadership-26.59Latest relative-leadership reading.
RS change-137.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 79% Model confidence 76%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength15/100Blend of value, momentum, and quality. Underlying universe rank 86; rank 1 is best.
Value25/100Relative valuation strength. Underlying universe rank 76; rank 1 is best.
Quality66/100Profitability and accounting quality. Underlying universe rank 35; rank 1 is best.
Momentum11/100Medium-term price momentum. Underlying universe rank 90; rank 1 is best.
Growth89/100Revenue and earnings growth. Underlying universe rank 12; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
12.6x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-28.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
99.8%
Gross profit retained from each unit of revenue.
Operating margin
-266.1%
Operating profit retained from revenue.
Free-cash-flow margin
-177.9%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
115.4%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-31.4%
Net share repurchases relative to market value.
Shareholder yield
-31.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
2.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

COYA shows mixed options pressure with a 35/100 conviction score, put-call volume ratio of n/a, expected move of 25.3%, and Sharemaestro trend signal active.

Conviction35/100
Expected move25.3%
Put/call volume
Pressure11
Speculation0
Volatility96
Trend agreement81
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment57/100

Weighted news tone is neutral across 41 relevant articles.

14 positive · 25 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move25.3%Nearest-chain priced movement where available.
52-week drawdown-45.2%Distance below the 52-week high.
13-week volatility9.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+20.7%Week of 15 May.
Worst week-13.7%Week of 17 Jul.
Latest week-6.4%Week of 24 Jul.

Shape of recent returns

Strong gains7
Modest gains4
Flat weeks0
Modest losses7
Sharp losses8
Recent vol9.2%13-week weekly-return volatility.
Base vol7.5%52-week weekly-return volatility.
Up/down split22/30Count of positive and negative weeks in the 52-week window.
Average skew6.3% / -5.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape29/100

Trend, activity pressure, participation, and risk combine to a 29/100 tape read.

 Indicator analysis38/100

Latest 12-week confirmation: trend 2/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.27; No reversal markers Factors29/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 94; Small Cap Core rank 83 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options54/100

COYA shows mixed options pressure with a 35/100 conviction score, put-call volume ratio of n/a, expected move of 25.3%, and Sharemaestro trend signal active.

Mixed · Options-market disagreement · Expected move 25.3% Sentiment57/100

Weighted news tone is neutral across 41 relevant articles.

1 Healthcare Stock to Keep an Eye On and 2 We Avoid Insiders50/100

No recent insider transaction evidence is stored.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20264.25 USD-6.4%4.68 USD6.05 USD0.85-26.591.0MOn
17 Jul 20264.54 USD-13.7%4.72 USD6.05 USD1.25-23.801.8MOn
10 Jul 20265.26 USD-10.2%4.75 USD6.05 USD1.33-16.111.7MOff
3 Jul 20265.86 USD6.5%4.78 USD6.04 USD1.12-5.66804.6KOff
26 Jun 20265.50 USD11.8%4.79 USD6.03 USD0.97-11.191.2MOff
19 Jun 20264.92 USD3.8%4.82 USD6.02 USD0.78-24.61878.6KOff
12 Jun 20264.74 USD7.2%4.86 USD6.02 USD0.70-26.05583.7KOff
5 Jun 20264.42 USD-8.3%4.89 USD6.02 USD0.86-30.081.1MOff
29 May 20264.82 USD0.2%4.94 USD6.02 USD0.64-27.94356.1KOff
22 May 20264.81 USD-3.0%4.99 USD6.02 USD0.40-26.60583.8KOff
15 May 20264.96 USD20.7%5.04 USD6.02 USD0.30-24.171.5MOff
8 May 20264.11 USD-1.4%5.09 USD6.02 USD0.08-37.94628.6KOff
1 May 20264.17 USD-3.5%5.15 USD6.03 USD-0.07-34.48511.8KOff
24 Apr 20264.32 USD-9.6%5.22 USD6.03 USD-0.31-32.02916.2KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.